Drugs / ASPARTYL-ALANYL-DIKETOPIPERAZINE
ASPARTYL-ALANYL-DIKETOPIPERAZINE
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials · 1 met primary | ||||||
| Phase 1 | NCT04880161 | Jul → Dec 2021 | COVID-19 | Ampio Pharmaceuticals. Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04606784 | Oct 2020 → Jun 2021 | COVID-19 | Ampio Pharmaceuticals. Inc. | Completed | Met primary |
| Phase 1 | NCT04456452 | Jul → Sep 2020 | COVID-19 | Ampio Pharmaceuticals. Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02762760 | May → Nov 2016 | osteoarthritis, hand | Ampio Pharmaceuticals. Inc. | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT02184156 | Jun 2014 → Oct 2015 | osteoarthritis, knee | Ampio Pharmaceuticals. Inc. | Completed | Met primary |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT04839965 | Jul 2021 → Feb 2022 | COVID-19 | Ampio Pharmaceuticals. Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04868890 | Jun 2021 → Feb 2022 | COVID-19 | Ampio Pharmaceuticals. Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01839331 | Mar → Aug 2013 | osteoarthritis, knee | Ampio Pharmaceuticals. Inc. | Completed | Met primary |
| Phase 36 trials · 1 met primary · 4 missed | ||||||
| Phase 3 | NCT03988023 | Jun 2019 → Jul 2021 | osteoarthritis, knee | Ampio Pharmaceuticals. Inc. | Terminated | Missed primary |
| Phase 3 | NCT03349645 | Dec 2017 → Oct 2018 | osteoarthritis, knee | Ampio Pharmaceuticals. Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03182686 | Jun → Dec 2017 | osteoarthritis, knee | Ampio Pharmaceuticals. Inc. | Completed | Met primary |
| Phase 3 | NCT02556710 | Sep 2015 → Jun 2016 | osteoarthritis, knee | Ampio Pharmaceuticals. Inc. | Completed | Missed primary |
| Phase 3 | NCT02242435 | Sep 2014 → Apr 2015 | osteoarthritis, knee | Ampio Pharmaceuticals. Inc. | Completed | Missed primary |
| Phase 3 | NCT02024529 | Jan → May 2014 | osteoarthritis, knee | Ampio Pharmaceuticals. Inc. | Completed | Missed primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASPARTYL-ALANYL-DIKETOPIPERAZINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297349 ↗ |
| Known as | AMP5A | “An inhalation form of a novel biologic drug, AMP5A, is being developed as an immunomodulatory agent to treat dysregulated immune responses and is being studied in hospitalized...” PMID 34775578 ↗ Nov 2021 |
| Known as | Ampion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02184156 ↗ |
| Known as | Da-dkp | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297349 ↗ |
| Known as | DMI-9523 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297349 ↗ |
| Known as | LMWF-5A | “The low-molecular-weight fraction of 5% human serum albumin (LMWF-5A) is being developed to treat the signs and symptoms of severe osteoarthritis of the knee.” PMID 29156068 ↗ Nov 20172“The Low Molecular Weight Fraction of 5% human serum Albumin (LMWF-5A) is in development to treat severe OAK.” PMID 29910837 ↗ Jun 2018 “Ampion (LMWF-5A) is a product of Ampio Pharmaceuticals.” PMID 24498399 ↗ Feb 2014 |
| Modality | Protein / enzyme biologic | “The Low Molecular Weight Fraction of 5% human serum Albumin (LMWF-5A) is being investigated as a treatment for knee pain from osteoarthritis.” PMID 24498399 ↗ Feb 2014 |
| Route | Other | “intra-articular (IA) injection” NCT02024529 ↗ |